Antifungal Therapy Changes in Invasive Aspergillosis Patients
Author Information
Author(s): Barbara D. Alexander, Melissa Johnson, Mark Bresnik, Vamshi Ruthwik Anupindi, Lia Pizzicato, Mitchell DeKoven, Belinda Lovelace, Craig I. Coleman
Primary Institution: Duke University
Hypothesis
What are the patterns of antifungal therapy changes in patients with invasive aspergillosis?
Conclusion
Most patients with invasive aspergillosis required changes to their antifungal therapy, indicating the complexity of treatment.
Supporting Evidence
- 59.3% of patients changed their antifungal therapy.
- Voriconazole was the most commonly used antifungal agent.
- Patients who changed therapy had shorter treatment durations on their first and second lines.
- Over 80% of patients who did not change therapy completed their course successfully.
- Combination therapies were more common in patients who changed their antifungal therapy.
Takeaway
Many people with a serious lung infection called invasive aspergillosis need to change their medicine because it doesn't work well or causes side effects.
Methodology
This was a retrospective, observational cohort study using US claims data to analyze antifungal therapy patterns in patients with invasive aspergillosis.
Potential Biases
Potential misclassification of invasive aspergillosis cases and lack of clinical context for treatment decisions.
Limitations
The study relied on claims data, which may lead to misclassification of cases and lack of clinical data to explain therapy changes.
Participant Demographics
Patients were primarily around 62 years old, more male than female, and mostly had Medicare or commercial insurance.
Statistical Information
P-Value
<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website